05:19 PM EDT, 10/03/2024 (MT Newswires) -- AbbVie ( ABBV ) said late Thursday its Q3 results will include acquired in-process research and development and milestones expense of $82 million on a pre-tax basis, representing an unfavorable impact of $0.04 to both GAAP and non-GAAP EPS.

The company said it now expects adjusted EPS of $2.88 to $2.92 for Q3 and $10.67 to $10.87 for the full year. Analysts polled by Capital IQ expected $2.95 for the quarter and $10.87 for the year.

Price: 194.74, Change: -0.71, Percent Change: -0.36